Michael J. Hayman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Michael J. Hayman has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Nobuhide Ueki
3 shared publicationsHong-Ling Zhao
Department of Molecular Genetics and Microbiology, Stony Brook University, Stony Brook, NY 11794-5222, USA
2 shared publicationsIrene Ischenko
Department of Molecular Genetics and Microbiology, State University of New York at Stony Brook, Stony Brook, NY 11794-5222, USA
2 shared publicationsJae Cheal Yoo
Department of Molecular Genetics and Microbiology, State University of New York at Stony Brook, Stony Brook, NY 11794-5222, USA
2 shared publicationsAlicia Colombo
Programa de Anatomía y Biología del Desarrollo, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile. Santiago, Chile
1 shared publicationDiego A. Rojas
Programa de Biología Celular y Molecular, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile. Santiago, Chile
1 shared publication
Latest Publications
- 1 June 2011
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 409 (3) , 539-543
Identification of Ski as a target for Aurora A kinase
- 1 June 2011
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 409 (3) , 539-543
Identification of Ski as a target for Aurora A kinase
- 1 September 2010
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 399 (4) , 623-628
The Ski protein negatively regulates Siah2-mediated HDAC3 degradation
- 1 September 2010
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 399 (4) , 623-628
The Ski protein negatively regulates Siah2-mediated HDAC3 degradation
- 31 March 2009
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 383 (1) , 119-124
The Ski protein can inhibit ligand induced RARα and HDAC3 degradation in the retinoic acid signaling pathway
- 31 March 2009
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 383 (1) , 119-124
The Ski protein can inhibit ligand induced RARα and HDAC3 degradation in the retinoic acid signaling pathway
- Open Access
- 6 October 2008
- Published by Springer Nature in Oncogene
- Vol. 28 (2) , 279-288
The RON receptor tyrosine kinase promotes MSP-independent cell spreading and survival in breast epithelial cells
The recepteur d'origine nantais (RON) is a receptor tyrosine kinase (RTK) in the scatter factor family, which includes the c-Met receptor. RON exhibits increased expression in a significant number of human breast cancer tissues as well as in many established breast cancer cell lines. Recent studies have indicated that in addition to ligand-dependent signaling events, RON also promotes signals in the absence of its only known ligand, MSP, when expressed in epithelial cells. In this study, we found that when expressed in MCF-10A breast epithelial cells, RON exhibits both MSP-dependent and MSP-independent signaling, which lead to distinct biological outcomes. In the absence of MSP, RON signaling promotes cell survival, increased cell spreading and enhanced migration in response to other growth factors. However, both RON-mediated proliferation and migration require the addition of MSP in MCF-10A cells. Both MSP-dependent and MSP-independent signaling by RON are mediated in part by Src family kinases. These data suggest that RON has two alternative modes of signaling that can contribute to oncogenic behavior in normal breast epithelial cells.
- 6 October 2008
- Published by Springer Nature in Oncogene
- Vol. 28 (2) , 279-288
Open AccessThe RON receptor tyrosine kinase promotes MSP-independent cell spreading and survival in breast epithelial cells
The recepteur d'origine nantais (RON) is a receptor tyrosine kinase (RTK) in the scatter factor family, which includes the c-Met receptor. RON exhibits increased expression in a significant number of human breast cancer tissues as well as in many established breast cancer cell lines. Recent studies have indicated that in addition to ligand-dependent signaling events, RON also promotes signals in the absence of its only known ligand, MSP, when expressed in epithelial cells. In this study, we found that when expressed in MCF-10A breast epithelial cells, RON exhibits both MSP-dependent and MSP-independent signaling, which lead to distinct biological outcomes. In the absence of MSP, RON signaling promotes cell survival, increased cell spreading and enhanced migration in response to other growth factors. However, both RON-mediated proliferation and migration require the addition of MSP in MCF-10A cells. Both MSP-dependent and MSP-independent signaling by RON are mediated in part by Src family kinases. These data suggest that RON has two alternative modes of signaling that can contribute to oncogenic behavior in normal breast epithelial cells.
- 1 May 2007
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 356 (4) , 906-911
Annexin II binds to SHP2 and this interaction is regulated by HSP70 levels
- 1 May 2007
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 356 (4) , 906-911
Annexin II binds to SHP2 and this interaction is regulated by HSP70 levels
- 3 November 2006
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 351 (4) , 979-985
HSP70 binds to SHP2 and has effects on the SHP2-related EGFR/GAB1 signaling pathway
- 3 November 2006
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 351 (4) , 979-985
HSP70 binds to SHP2 and has effects on the SHP2-related EGFR/GAB1 signaling pathway
- Open Access
- 1 December 2004
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 24 (23) , 10118-10125
Ski Negatively Regulates Erythroid Differentiation through Its Interaction with GATA1
The Ski oncoprotein dramatically affects cell growth, differentiation, and/or survival. Recently, Ski was shown to act in distinct signaling pathways including those involving nuclear receptors, transforming growth factor β, and tumor suppressors. These divergent roles of Ski are probably dependent on Ski's capacity to bind multiple partners with disparate functions. In particular, Ski alters the growth and differentiation program of erythroid progenitor cells, leading to malignant leukemia. However, the mechanism underlying this important effect has remained elusive. Here we show that Ski interacts with GATA1, a transcription factor essential in erythropoiesis. Using a Ski mutant deficient in GATA1 binding, we show that this Ski-GATA1 interaction is critical for Ski's ability to repress GATA1-mediated transcription and block erythroid differentiation. Furthermore, the repression of GATA1-mediated transcription involves Ski's ability to block DNA binding of GATA1. This finding is in marked contrast to those in previous reports on the mechanism of repression by Ski, which have described a model involving the recruitment of corepressors into DNA-bound transcription complexes. We propose that Ski cooperates in the process of transformation in erythroid cells by interfering with GATA1 function, thereby contributing to erythroleukemia.
- 1 December 2004
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 24 (23) , 10118-10125
Open AccessSki Negatively Regulates Erythroid Differentiation through Its Interaction with GATA1
The Ski oncoprotein dramatically affects cell growth, differentiation, and/or survival. Recently, Ski was shown to act in distinct signaling pathways including those involving nuclear receptors, transforming growth factor β, and tumor suppressors. These divergent roles of Ski are probably dependent on Ski's capacity to bind multiple partners with disparate functions. In particular, Ski alters the growth and differentiation program of erythroid progenitor cells, leading to malignant leukemia. However, the mechanism underlying this important effect has remained elusive. Here we show that Ski interacts with GATA1, a transcription factor essential in erythropoiesis. Using a Ski mutant deficient in GATA1 binding, we show that this Ski-GATA1 interaction is critical for Ski's ability to repress GATA1-mediated transcription and block erythroid differentiation. Furthermore, the repression of GATA1-mediated transcription involves Ski's ability to block DNA binding of GATA1. This finding is in marked contrast to those in previous reports on the mechanism of repression by Ski, which have described a model involving the recruitment of corepressors into DNA-bound transcription complexes. We propose that Ski cooperates in the process of transformation in erythroid cells by interfering with GATA1 function, thereby contributing to erythroleukemia.
- 1 November 2003
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 23 (21) , 7875-7886
Molecular Mechanism for a Role of SHP2 in Epidermal Growth Factor Receptor Signaling
Read the full review for this F1000Prime recommended article: Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling.
- 1 November 2003
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 23 (21) , 7875-7886
Molecular Mechanism for a Role of SHP2 in Epidermal Growth Factor Receptor Signaling
Read the full review for this F1000Prime recommended article: Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling.
- 9 October 2003
- Published by Springer Nature in Oncogene
- Vol. 22 (44) , 6909-6918
The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3
Receptor tyrosine kinases (RTKs) such as the fibroblast growth factor receptor (FGFR) and the epidermal growth factor receptor are overexpressed in a variety of cancers. In addition to overexpression, the FGFRs are found mutated in some cancers. The Src homology 2 domain-containing phosphotyrosine phosphatase (SHP2) is a critical mediator of RTK signaling, but its role in oncogenic RTK-induced cell transformation and cancer development is largely unknown. In the current report, we demonstrate that constitutively activated FGFR3 (K/E-FR3) transforms NIH-3T3 cells, and that SHP2 is a critical mediator of this transformation. Infection of K/E-FR3-transformed 3T3 cells with a retrovirus carrying a dominant-negative mutant of SHP2 (C/S-SHP2) retarded cell growth, reversed the transformation phenotype and inhibited focus-forming ability. Furthermore, treatment of K/E-FR3-transformed NIH-3T3 cells with PD98059 or LY294002, specific inhibitors of MEK and PI3K, respectively, inhibited focus formation. Biochemical analysis showed that K/E-FR3 activates the Ras-ERK and the PI3K signaling pathways, and that the C/S SHP2 mutant suppressed this effect via competitive displacement of interaction of the endogenous SHP2 with FRS2. However, the C/S SHP2 protein did not show any effect on receptor autophosphorylation, FRS2 tyrosine phosphorylation or interaction of Grb2 with K/E-FR3 or FRS2. Together, the results show that K/E-FR3 is transforming and that the Ras-ERK and the PI3K-Akt signaling pathways, which are positively regulated by SHP2, are important for K/E-FR3-induced transformation.
- 9 October 2003
- Published by Springer Nature in Oncogene
- Vol. 22 (44) , 6909-6918
The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3
Receptor tyrosine kinases (RTKs) such as the fibroblast growth factor receptor (FGFR) and the epidermal growth factor receptor are overexpressed in a variety of cancers. In addition to overexpression, the FGFRs are found mutated in some cancers. The Src homology 2 domain-containing phosphotyrosine phosphatase (SHP2) is a critical mediator of RTK signaling, but its role in oncogenic RTK-induced cell transformation and cancer development is largely unknown. In the current report, we demonstrate that constitutively activated FGFR3 (K/E-FR3) transforms NIH-3T3 cells, and that SHP2 is a critical mediator of this transformation. Infection of K/E-FR3-transformed 3T3 cells with a retrovirus carrying a dominant-negative mutant of SHP2 (C/S-SHP2) retarded cell growth, reversed the transformation phenotype and inhibited focus-forming ability. Furthermore, treatment of K/E-FR3-transformed NIH-3T3 cells with PD98059 or LY294002, specific inhibitors of MEK and PI3K, respectively, inhibited focus formation. Biochemical analysis showed that K/E-FR3 activates the Ras-ERK and the PI3K signaling pathways, and that the C/S SHP2 mutant suppressed this effect via competitive displacement of interaction of the endogenous SHP2 with FRS2. However, the C/S SHP2 protein did not show any effect on receptor autophosphorylation, FRS2 tyrosine phosphorylation or interaction of Grb2 with K/E-FR3 or FRS2. Together, the results show that K/E-FR3 is transforming and that the Ras-ERK and the PI3K-Akt signaling pathways, which are positively regulated by SHP2, are important for K/E-FR3-induced transformation.